Literature DB >> 18542844

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.

Osvaldo L Podhajcer1, Lorena Gabriela Benedetti, Maria Romina Girotti, Federico Prada, Edgardo Salvatierra, Andrea S Llera.   

Abstract

Tumor growth is essentially the result of an evolving cross-talk between malignant and surrounding stromal cells (fibroblasts, endothelial cells and inflammatory cells). This heterogeneous mass of extracellular matrix and intermingled cells interact through cell-cell and cell-matrix contacts. Malignant cells also secrete soluble proteins that reach neighbor stromal cells, forcing them to provide the soil on which they will grow and metastasize. Different studies including expression array analysis identified the matricellular protein SPARC as a marker of poor prognosis in different cancer types. Further evidence demonstrated that high SPARC levels are often associated with the most aggressive and highly metastatic tumors. Here we describe the most recent evidence that links SPARC with human cancer progression, the controversy regarding its role in certain human cancers and the physiological processes in which SPARC is involved: epithelial-mesenchymal transition, immune surveillance and angiogenesis. Its relevance as a potential target in cancer therapy is also discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18542844     DOI: 10.1007/s10555-008-9146-7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  67 in total

Review 1.  Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.

Authors:  Helena Verdaguer; Tamara Saurí; Teresa Macarulla
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

Authors:  Miguel Martín; José I Chacón; Antonio Antón; Arrate Plazaola; Elena García-Martínez; Miguel A Seguí; Pedro Sánchez-Rovira; José Palacios; Lourdes Calvo; Carmen Esteban; Enrique Espinosa; Agusti Barnadas; Norberto Batista; Angel Guerrero; Montserrat Muñoz; Estefania Romio; César Rodríguez-Martín; Rosalía Caballero; María I Casas; Federico Rojo; Eva Carrasco; Silvia Antolín
Journal:  Oncologist       Date:  2017-07-12

3.  Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1.

Authors:  Yoshihiro Suzuki; Takashi Oshima; Kazue Yoshihara; Kentaro Sakamaki; Toru Aoyama; Haruhiko Cho; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Toshio Imada; Munetaka Masuda
Journal:  Oncol Lett       Date:  2018-03-13       Impact factor: 2.967

4.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

5.  Screening the pathogenic genes and pathways related to DMBA (7,12-dimethylbenz[a]anthracene)-induced transformation of hamster oral mucosa from precancerous lesions to squamous cell carcinoma.

Authors:  Dan Chen; Kai Yang; Jie Mei; Guodong Zhang; Xiaoqiang Lv; Li Xiang
Journal:  Oncol Lett       Date:  2011-04-26       Impact factor: 2.967

6.  Application of albumin-based nanoparticles in the management of cancer.

Authors:  Xinzhe Yu; Chen Jin
Journal:  J Mater Sci Mater Med       Date:  2015-11-26       Impact factor: 3.896

7.  Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.

Authors:  Jun Gao; Jian Song; Haojie Huang; Zhaoshen Li; Yiqi Du; Jia Cao; Minghui Li; Shunli Lv; Han Lin; Yanfang Gong
Journal:  J Exp Clin Cancer Res       Date:  2010-03-26

8.  Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival.

Authors:  Jie Yin; Guowei Chen; Yucun Liu; Si Liu; Pengyuan Wang; Yuanlian Wan; Xin Wang; Jing Zhu; Hongqiao Gao
Journal:  J Exp Clin Cancer Res       Date:  2010-06-02

9.  Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose.

Authors:  Katrina Kos; Steve Wong; Bee Tan; Anders Gummesson; Margareta Jernas; Niclas Franck; David Kerrigan; Fredrik H Nystrom; Lena M S Carlsson; Harpal S Randeva; Jonathan H Pinkney; John P H Wilding
Journal:  Diabetes       Date:  2009-06-09       Impact factor: 9.461

10.  Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.

Authors:  G Chen; X Tian; Z Liu; S Zhou; B Schmidt; D Henne-Bruns; M Bachem; M Kornmann
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.